On April 3, 2018, Pfizer and Allogene Therapeutics, a biotechnology company, announced that they have entered into an asset contribution agreement, under which Pfizer will transfer assets related to allogeneic chimeric antigen receptor T-cell (CAR-T) therapy in its portfolio to Allogene.
You may also like
Pharmaceutical Sales Customer Engagement –...
AstraZeneca’s Polyneuropathy Treatment Recommended...
Designing a Strategic Roadmap for Seamless Product...
AAPS PharmSci 360: LBFs and Tackling Oral Biologic...
CHMP Gives Positive Opinion to Novo Nordisk Hemophilia...
GSK, Cambridge to Partner on R&D for Kidney and...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.